CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society

Table 5 The number of patients followed up categorized by the MMD threshold for prescribing a CGRPmAb

MMD threshold for prescribing CGRPmAbs	No. of patients with migraine who are followed up regularly			No. of patients with migraine who are followed up regularly and have ever used CGRPmAbs
MMD threshold for prescribing CGRPmAbs	N^a	Median [Q1, Q3]	p-value	N^a	Median [Q1, Q3]	p-value
≥ 4	71	30 [20, 100]	0.0026	71	10 [3, 30]	0.0109
≥ 6	68	35 [20, 100]		68	6 [3, 22.5]
≥ 8	76	90 [30, 240]		76	14.5 [6, 50]
≥ 10	81	50 [20, 100]		81	7 [3, 20]
≥ 12	4	17.5 [12.5, 70]		4	4.5 [2.5, 22.5]
≥ 15	12	56 [20, 155]		12	5.5 [3.5, 15.0]

The data are presented as median [first quartile, third quartile]
MMD Monthly migraine days, CGRPmAb Anti-calcitonin gene-related peptide monoclonal antibody, No Number
^aN indicates the number of physicians, Q1: first quartile, Q3: third quartile

ISSN: 1129-2377